deucrictibant XR (PHVS719) — Topline data
3Q2026
Topline data from CHAPTER-3, a pivotal Phase 3 study of deucrictibant XR for the prophylaxis of HAE attacks, expected in 3Q2026Source filing
PHVS biotech catalysts & pipeline
PHARVARIS NV · Data as of 2026-09-08
Upcoming catalysts
deucrictibant IR (PHVS416) — PDUFA
Apr 23
Deucrictibant IR NDA under review by the FDA with PDUFA date of April 23, 2027; MAA validated by the EMA in July 2026Source filing